GL Capital has helped China’s SciClone Pharmaceuticals position itself for the future while continuing to monetize its key legacy drug. A Hong Kong listing was the reward
SciClone Pharmaceuticals takes a counterintuitive approach to China biotech. While many of its peers are developing innovative drugs based on molecules newly-licensed from the US, SciClone’s core product...
The Riverside Group has bought Australian injury management and occupational rehabilitation services provider Nabenet as part of a workplace wellbeing rollup strategy.
Dreame, a Beijing-headquartered vacuum cleaner maker backed by smart phone and consumer electronics giant Xiaomi, has raised RMB3.6 billion ($563 million) in Series C funding.
Primavera Capital Group has invested $600 million in two subsidiaries of Envision Group, a China-based manufacturer of wind turbines, smart batteries, and renewable energy management systems.
India’s Axis Bank has launched a distress buyout fund targeting INR35 billion ($468 million) via its asset management business.